Pancreatic cancer patient Ben Sasse sees 'massive' tumor reduction with experimental new drug [FOX News]
Revolution Medicines, Inc. (RVMD)
Company Research
Source: FOX News
Months after revealing his stage 4 cancer diagnosis , former U.S. Sen. Ben Sasse is speaking out about an experimental therapy that could extend his life. Sasse, a Republican who represented Nebraska between 2015 and 2023, shared in December 2025 that he has metastatic pancreatic cancer, which has spread to multiple organs — including his liver and lungs. After initially being given three to four months to live, Sasse, 54, entered a clinical trial for a drug called daraxonrasib, an oral therapy (pill) that is designed to block the defective gene that triggers uncontrolled cellular growth. The California-based drugmaker, Revolution Medicines, recently shared data from a phase 3 clinical trial of people with metastatic pancreatic cancer who did not respond to standard chemotherapy. Patients on the treatment lived a median of 13 months, compared to around six months for those who continued with chemo. "I have much, much less pain than I had four months ago when I was diagnosed
Show less
Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVMD alerts
High impacting Revolution Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
RVMD
News
- Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026GlobeNewswire
- Erasca Shares Plunge 48% After Trial Patient Death, Patent Dispute Emerges [Yahoo! Finance]Yahoo! Finance
- Revolution's on a pancreatic cancer winning streak. What comes next for the biotech? [Yahoo! Finance]Yahoo! Finance
- Assessing Revolution Medicines (RVMD) Valuation After Positive RASolute 302 And Zoldonrasib Clinical Updates [Yahoo! Finance]Yahoo! Finance
- Erasca shares sink after patient death in early-stage cancer drug trial [Yahoo! Finance Canada]Yahoo! Finance Canada
RVMD
Earnings
- 2/25/26 - Miss
RVMD
Sec Filings
- 4/29/26 - Form 4
- 4/28/26 - Form DEFA14A
- 4/28/26 - Form ARS
- RVMD's page on the SEC website